Bart Henderson

Co-Founder at Torque Therapeutics, Inc.

Bart Henderson

Bart Henderson

Co-Founder at Torque Therapeutics, Inc.

Overview
Career Highlights

Torque Therapeutics, Inc.
Rhythm Pharmaceuticals, Inc.
Allergan GI Corp.

RelSci Relationships

618

Number of Boards

2

Birthday

1959

Age

60

Contact Data
Trying to get in touch with Bart Henderson? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Bart Henderson likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Permeon Biologics, Inc.

Relationship likelihood: Strong

Co-Founder at Torque Therapeutics, Inc.

Relationship likelihood: Strong

Director, Chief Executive Officer & President at Rhythm Pharmaceuticals, Inc.

Relationship likelihood: Strong

Operating Advisor at Clayton Dubilier & Rice LLC

Relationship likelihood: Strong

Head, Department of Biological Engineering at Massachusetts Institute of Technology - School of Engineering

Relationship likelihood: Strong

Executive Partner at Mpm Capital LLC

Relationship likelihood: Strong

Venture Partner at 5AM Venture Management LLC

Relationship likelihood: Strong

Former General Manager at Biogen, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Anokion SA

Relationship likelihood: Strong

Director of Cellular Immunotherapy at Massachusetts General Hospital Cancer Center

Relationship likelihood: Strong

Paths to Bart Henderson
Potential Connections via
Relationship Science
You
Bart Henderson
Co-Founder at Torque Therapeutics, Inc.
Education
BA

Amherst College educates men and women of exceptional potential from all backgrounds so that they may seek, value, and advance knowledge, engage the world around them, and lead principled lives of consequence. Amherst brings together the most promising students, whatever their financial need, in order to promote diversity of experience and ideas within a purposefully small residential community. Working with faculty, staff, and administrators dedicated to intellectual freedom and the highest standards of instruction in the liberal arts, Amherst undergraduates assume substantial responsibility for undertaking inquiry and for shaping their education within and beyond the curriculum. Amherst College is committed to learning through close colloquy and to expanding the realm of knowledge through scholarly research and artistic creation at the highest level. Its graduates link learning with leadership—in service to the College, to their communities, and to the world beyond.

MBA

The Tuck School of Business at Dartmouth is the graduate business school of Dartmouth College in Hanover, New Hampshire, in the United States. Tuck is one of six Ivy league business schools. Founded in 1900, Tuck was the first institution to offer a master's degree in the field of business administration

Career History
Vice President-Business Development
2001 - 2003

At Ironwood, we seek to transform knowledge into medicines that make a difference for patients. Patients shape our business. They influence our drugmaking process, helping us to understand and address their unmet medical needs, whether we’re creating a new medicine or tackling the equally challenging task of delivering that medicine to people around the world. Our employees shape our success. Since our founding in 1998, each of our employees has held shares in the company. Being owners of Ironwood means we are all careful stewards of our resources: we take a data-driven approach in which we celebrate definitive answers – whether those answers support holding steady or changing course – and we challenge every program to earn its way forward. Our discovery and development processes have generated a product that’s approved in the United States and in the European Union, as well as a robust pipeline. As we continue to do drugmaking well, we hope to inspire the support of our shareholders and earn the right to do it again – building an enduring pharmaceutical company that understands and addresses people’s needs.

Marketing Manager-NEUPOGEN
1991 - 1996

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Founder
2008 - Prior

Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Boston, MA.

Boards & Committees
Director
Current

Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA.

Director
Tenure Unconfirmed

Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ.

Political Donations
$1,000
2008

Former President of United States

Transactions
Details Hidden

Torque Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Rhythm Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Torque Therapeutics, Inc. raised money in a private placement transaction

Investments
Details Hidden

Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA.

Details Hidden

Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.

Details Hidden

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Bart Henderson. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Bart Henderson's profile does not indicate a business or promotional relationship of any kind between RelSci and Bart Henderson.